Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). SCYNEXIS's share price for the quarter that ended in Dec. 2023 was $2.23. SCYNEXIS's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 37.2 Mil. Therefore, SCYNEXIS's market cap for the quarter that ended in Dec. 2023 was $83.0 Mil.
SCYNEXIS's quarterly market cap
declined
from Jun. 2023 ($109.7 Mil) to Sep. 2023 ($84.8 Mil) and
declined
from Sep. 2023 ($84.8 Mil) to Dec. 2023 ($83.0 Mil).
SCYNEXIS's annual market cap
declined
from Dec. 2021 ($175.1 Mil) to Dec. 2022 ($51.0 Mil) but then
increased
from Dec. 2022 ($51.0 Mil) to Dec. 2023 ($83.0 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. SCYNEXIS's Enterprise Value for Today is $-1.1 Mil.
SCYNEXIS Market Cap Historical Data
The historical data trend for SCYNEXIS's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SCYNEXIS's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Market Cap distribution charts can be found below:
* The bar in red indicates where SCYNEXIS's Market Cap falls into.
SCYNEXIS Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
SCYNEXIS's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCYNEXIS (NAS:SCYX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
SCYNEXIS Market Cap Related Terms
Thank you for viewing the detailed overview of SCYNEXIS's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SCYX has been successfully added to your 